Neonatal urea cycle disorders: emergency management and dialysis
Neonatal urea cycle disorders (UCDs) are uncommon inherited conditions, but they can become life-threatening within hours. A newborn who initially appears well may develop poor feeding, vomiting, lethargy, abnormal tone, seizures or respiratory changes as ammonia accumulates in the blood. Early recognition and immediate treatment are more important than waiting for a complete genetic diagnosis.
These disorders impair the conversion of nitrogen into urea for safe excretion. The result is hyperammonaemia, with ammonia crossing the blood–brain barrier and causing cerebral oedema, seizures and permanent neurological injury. The clinical picture may resemble sepsis, hypoglycaemia, hypoxic injury or an inborn error of organic acid metabolism, so ammonia must be measured promptly in an unwell neonate.
The former FAOPS 2020 archive reflects the scientific environment in which perinatal and neonatal medicine was discussed across Asia and Oceania. For clinicians in Australia, the same principles apply whether a baby presents in a tertiary neonatal intensive care unit in Melbourne or requires urgent retrieval from a regional hospital in Queensland, New South Wales or Western Australia.
| Emergency priority | Practical approach | Why it matters |
|---|---|---|
| Confirm the problem | Obtain a properly handled plasma ammonia sample and repeat an unexpected result urgently | Delayed processing or contamination can produce misleading values |
| Stop nitrogen load | Temporarily withhold enteral protein while maintaining high-energy intravenous support | Reduces further ammonia generation without allowing catabolism |
| Provide pathway treatment | Use intravenous glucose, lipid where appropriate, nitrogen scavengers and disease-specific cofactors under metabolic advice | Creates alternative routes for nitrogen disposal |
| Assess dialysis need | Involve paediatric nephrology and intensive care early when ammonia is severe, rising or unresponsive | Extracorporeal clearance may be required before neurological injury progresses |
| Protect the brain | Treat seizures, manage ventilation and avoid prolonged hypotension or hypoxia | Neurological outcome depends on rapid correction and supportive care |
Recognising the neonatal presentation
A UCD can present in the first few days after birth, often after a period of apparently normal feeding. The infant may become increasingly sleepy, feed poorly, vomit or develop tachypnoea that is mistaken for respiratory disease. Hypotonia may progress to irritability, abnormal movements, seizures, coma or unexplained encephalopathy. In a male newborn, severe early disease raises particular concern for ornithine transcarbamylase deficiency, although any sex can be affected by several UCDs.
The initial assessment should include bedside glucose, blood gas, lactate, electrolytes, liver tests, ketones and ammonia. Plasma amino acids, urine orotic acid, urine organic acids and acylcarnitine testing help distinguish a proximal UCD from other metabolic emergencies. A respiratory alkalosis can be an early clue, while marked ketosis, lactic acidosis or hypoglycaemia may point towards another diagnosis. These patterns are helpful, but they must not delay treatment when ammonia is high.
Hyperammonaemia should also remain in the differential for a neonate with unexplained jaundice or neurological deterioration. The discussion of neonatal jaundice is relevant because visible jaundice can draw attention towards bilirubin while a separate metabolic crisis develops. Bilirubin, infection and ammonia may need assessment at the same time.
The first hour of treatment
Management begins with contacting a metabolic physician, neonatologist, paediatric intensivist and dietitian. Enteral protein is generally stopped temporarily during the acute phase, but calories must continue. Intravenous dextrose is used to suppress catabolism, with glucose delivery adjusted to the infant’s size, blood glucose and metabolic response. Lipid may be added when appropriate, particularly if extra energy is required, while clinicians monitor triglycerides and other complications.
Nitrogen-scavenging medicines such as sodium benzoate and sodium phenylacetate or phenylbutyrate provide alternative pathways for nitrogen excretion. Intravenous arginine is commonly used in several UCDs, while citrulline may be appropriate in selected disorders. The exact combination depends on the suspected enzyme defect, biochemical results, drug availability and specialist advice. Sodium load, fluid balance, potassium, acid–base status and cerebral status require frequent review.
Broad-spectrum antibiotics and cultures may be appropriate if sepsis is plausible, but a normal early examination or negative initial tests should not reassure clinicians when ammonia is elevated. A newborn can have infection and a metabolic disorder together. Intubation may be needed for airway protection, though ventilation and sedation should be managed carefully because hypotension and excessive hypocarbia can worsen cerebral perfusion.
Confirming the biochemical diagnosis
The ammonia sample should be collected in a free-flowing venous or arterial specimen, placed and transported according to local laboratory requirements, and processed urgently. A difficult heel-prick or delayed sample can be falsely high, so an unexpected result should be repeated without treating the result as harmless. A clearly elevated value in a symptomatic neonate is an emergency while confirmation proceeds.
Blood gas findings, plasma amino acids and urine orotic acid help define the likely block. Very low citrulline may occur in proximal defects such as carbamoyl phosphate synthetase I deficiency or ornithine transcarbamylase deficiency, while high citrulline suggests citrullinaemia type I in the appropriate context. Elevated argininosuccinic acid points towards argininosuccinic aciduria. These patterns guide therapy, but molecular testing is valuable for definitive diagnosis, family counselling and future pregnancy planning.
The clinical team should also exclude organic acidurias, fatty-acid oxidation disorders, liver failure, medication toxicity and other causes of encephalopathy. Imaging is not a substitute for metabolic testing. If seizures or altered consciousness persist, electroencephalography and neuroimaging may be required, but stabilisation and ammonia reduction take priority.
Preventing catabolism and clearing nitrogen
The central metabolic goal is to stop the infant breaking down endogenous protein. This requires adequate glucose delivery, careful fluid management and prompt treatment of fever, infection, pain and other physiological stressors. Protein should not be withheld for longer than necessary; once ammonia is controlled and the specialist team agrees, protein is reintroduced in measured amounts to support growth and prevent renewed catabolism.
Nitrogen scavengers remove nitrogen through alternative compounds excreted by the kidneys. Arginine or citrulline can replenish intermediates in the urea cycle, depending on the suspected defect. Some babies require cofactors or adjunctive medicines, including carglumic acid in selected situations where N-acetylglutamate synthase activation is impaired or the diagnosis remains uncertain. Dosing must follow an established metabolic protocol because errors can cause sodium excess, electrolyte disturbance or inadequate treatment.
Ammonia should be measured frequently during the acute phase, with the interval shortened when the concentration is rising or treatment is changing. Urine output, renal function, glucose, sodium, potassium, bicarbonate, lactate and osmolality also influence decisions. A falling number is reassuring, but neurological examination remains essential because brain injury can continue even after the laboratory result improves.
When dialysis becomes necessary
Dialysis should be considered early when ammonia is very high, continues to rise despite medical therapy, or fails to fall promptly after treatment begins. There is no single threshold that suits every newborn, because the decision depends on the absolute concentration, rate of change, clinical condition, access options and local expertise. Severe encephalopathy, seizures, coma or evidence of cerebral oedema should prompt urgent discussion rather than prolonged observation.
Continuous kidney replacement therapy, particularly continuous venovenous haemodiafiltration, is often preferred when a neonate needs sustained ammonia clearance and haemodynamic stability. Intermittent haemodialysis can remove ammonia rapidly where suitable equipment, vascular access and experienced staff are immediately available. Peritoneal dialysis is generally less efficient for fast ammonia removal, although local circumstances may affect the choice.
Vascular access, anticoagulation, temperature, blood pressure and circuit flow are major practical issues in a small infant. A dialysis plan should be agreed between neonatal intensive care, paediatric nephrology, metabolic medicine and the retrieval service. Ammonia can rebound if production remains high, so scavengers, energy support and treatment of the underlying disorder continue during extracorporeal therapy.
Coordinating care across Australia
Australia’s geography makes early escalation especially important. A baby in a metropolitan unit such as the Royal Children’s Hospital in Melbourne, Westmead in Sydney or the Queensland Children’s Hospital in Brisbane may have immediate access to metabolic and dialysis teams; a newborn in a rural or remote service may need rapid advice through state-based neonatal retrieval and telehealth pathways. The referring team should send serial ammonia results, blood gases, medication doses, weight and vascular-access details with the infant.
Transport planning must account for infusion security, temperature control, glucose monitoring and the possibility of sudden neurological deterioration. The team should clarify whether dialysis can begin at the receiving hospital and whether the infant needs transfer directly to a centre with neonatal extracorporeal capability. Australian public hospitals may operate under different state protocols, so the treating service should use its current local guideline rather than rely on a generic online dose chart.
Parents need clear, calm communication during a frightening emergency. Explain that the condition may be inherited, that treatment is time-critical and that genetic testing can clarify recurrence risk. Cultural safety, interpreter access and shared decision-making matter, particularly when families are travelling long distances or balancing care of other children. Later review should include developmental surveillance, metabolic nutrition planning and consideration of liver transplantation for severe recurrent disease.
Building a plan beyond the crisis
Once ammonia is controlled, the infant requires a carefully monitored protein and energy prescription. Specialist metabolic dietitians balance natural protein, essential amino acids, formula composition and growth requirements. Families are taught how to recognise early illness, start an emergency regimen and seek urgent ammonia testing during infections, poor feeding or vomiting. Written plans are particularly useful when families move between hospitals or travel during school holidays.
The underlying genetic diagnosis can influence prognosis and long-term treatment. Some children have episodic disease with good development when crises are prevented, while others sustain injury during the first presentation. Early developmental assessment, audiology, vision review and neurological follow-up help identify support needs. Genetic counselling may include testing parents and siblings and discussing prenatal or preimplantation options where appropriate.
Perinatal teams can also improve outcomes before birth when a familial UCD is known. Prenatal diagnosis, delivery planning and immediate access to metabolic advice may reduce the interval between birth and treatment. The broader principles of coordinated antenatal and postnatal planning also appear in discussions of congenital heart disease care, where early communication between maternity, neonatal and specialist services is equally important.
An unwell newborn with unexplained encephalopathy deserves an urgent ammonia measurement, rapid metabolic consultation and a coordinated plan for catabolism control and extracorporeal clearance. Australian clinicians should activate local neonatal retrieval and specialist pathways early, document serial results carefully and involve families throughout the emergency. Fast recognition and decisive treatment can preserve neurological function while the diagnosis is confirmed.
